Quantcast

Aeterna Zentaris to Present Poster on Pharmacological and Toxicological Data on Oral Synthetic Growth Hormone Secretagogue/Ghrelin Receptor Agonist, AEZS-130, at Upcoming ENDO Annual Meeting

June 14, 2010

QUEBEC CITY, June 14 /PRNewswire-FirstCall/ – Aeterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ), (the “Company”) a late-stage drug development company specialized in oncology and endocrine therapy, today announced that a poster on its oral synthetic growth hormone secretagogue/ghrelin receptor agonist, AEZS-130, will be presented at the upcoming 92nd Annual Endocrine Society (ENDO) Meeting and Expo, which will be held June 19 through 22, 2010 at the San Diego Convention Center in San Diego, California. AEZS-130 (Solorel(TM)) is currently in a Phase 3 trial as a diagnostic test for growth hormone deficiency in adults.

    Abstract #851112:  "Pharmacological and Toxicological Evaluation of
                          AEZS-130, a Novel, Oral Synthetic Growth Hormone
                          Secretagogue//Ghrelin Receptor Agonist for the
                          Diagnosis of Growth Hormone Deficiency", Babette
                          Aicher, Peter Schmidt, Elena Bresciani, Vittorio
                          Locatelli, Daniel Perrissoud, Michael Teifel

    Presenter:            Dr. Babette Aicher, Associate Director - Screening
                          & Profiling, Preclinical Development, Aeterna
                          Zentaris

    Date and Time:        Sunday, June 20, 2010, 1:30 pm - 3:30 pm
                          (local time)

    Poster Board #:     P2-340

    Location:             Halls D-G, San Diego Convention Center

A copy of this abstract is currently available on the ENDO website at www.endo-society.org.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.

SOURCE AETERNA ZENTARIS INC.


Source: newswire



comments powered by Disqus